Royalty Report: cardiac, Medical, Diagnostic – Collection: 291192

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • cardiac
  • Medical
  • Diagnostic
  • Drugs
  • Disease
  • Regenerative medicine
  • Specialty

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 291192

License Grant
The Licensor of the Netherlands grants to a license to any and all Intellectual Property Rights as may be agreed by the Parties and set forth from time to time in one or more addenda to this Agreement on the terms set forth herein and on such additional terms as may be set forth in such addenda. Any such Intellectual Property Rights are sometimes hereinafter referred to as Subject IP, and any such addendum is sometimes hereinafter referred to as a Licensing Addendum.  The License granted under this Licensing Addendum shall be exclusive.
License Property
The licensed property is for certain Intellectual Property Rights and capabilities in the field of cardiac disease markers, in particular in the area of heart failure.

For this Addendum 1, the following Intellectual Property Rights shall constitute Subject IP and
therefore be licensed:
—  all rights of any nature in and to patent/application entitled 'Method for identifying a subject at risk of developing heart failure by determining the level of Galactin-3 or Thrombospondin-2, and all related patents and patent applications.

Field of Use
The License granted under this Licensing Addendum shall permit Licensee to use and exploit the Licensor Pre-Existing IP and Jointly Developed IP for any purpose whatsoever.  The Field of Interest shall include the field of congestive heart failure.  Licensee owns advanced proteomic and metabolomic capabilities that are applied for biomarker discovery and validation.

IPSCIO Record ID: 291406

License Grant
The Licensor of the Netherlands grants to a license to any and all Intellectual Property Rights as may be agreed by the Parties and set forth from time to time in one or more addenda to this Agreement on the terms set forth herein and on such additional terms as may be set forth in such addenda. Any such Intellectual Property Rights are sometimes hereinafter referred to as Subject IP, and any such addendum is sometimes hereinafter referred to as a Licensing Addendum.  The License granted under this Licensing Addendum shall be exclusive.
License Property
The licensed property is for certain Intellectual Property Rights and capabilities in the field of cardiac disease markers, in particular in the area of heart failure.

For this Addendum 2, the following Intellectual Property Rights shall constitute Subject IP and
therefore be licensed:
—  all rights of any nature in and to patent/application entitled Peptides for use in diagnosing the
presence of ruptured atherosclerotic lesions in an individual and all related patents and patent applications.

Field of Use
The License granted under this Licensing Addendum shall permit Licensee to use and exploit the Licensor Pre-Existing IP and Jointly Developed IP for any purpose whatsoever.  The Field of Interest shall include the field of atherothrombotic vascular disease, including non-ischemia angina.  Licensee owns advanced proteomic and metabolomic capabilities that are applied for biomarker discovery and validation.

IPSCIO Record ID: 240578

License Grant
The University grants a worldwide, exclusive license under Licensed Subject matter to discover, research, develop, make, have made, use offer for sale, sell and import Licensed Products and Identified Products for use within Licensed Field.
License Property
Licensed Product means any compound, assay, method, reagent, technology, product or service comprising Licensed Subject Matter.

Licensed Subject Matter means inventions, discoveries, assays and processes covered by Patent Rights and/or Technology Rights within Licensed Field.

The patents are for Methods and Compositions Relating to Muscle Selective Calcineurin Interacting Protein (MCIP).

Field of Use
Licensed field means treatment, prevention, diagnosis and/or prognosis of cardiac hypertrophy, heart disease and heart failure; and determination of predisposition to cardiac hypertrophy, heart disease and heart failure.

IPSCIO Record ID: 230517

License Grant
The Licensor granted the Kuwait Licensee the exclusive right to the intellectual property for the licensed use and development in Kuwait and other GCC/Middle East countries.
License Property
The Intellectual Property relates to methods of repairing damaged heart tissue by transplanting myoblasts that express SDF-1 and other therapeutic proteins capable of recruiting other stem cells within a patient’s own body to the cell transplant area.

The IP includes products and technologies like MyoCell for the treatment of heart damage. These are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients.

MyoCell is an innovative clinical therapy designed to populate regions of scar tissue within a patient’s heart with autologous muscle cells, or cells from a patient’s body, for the purpose of improving cardiac function in chronic heart failure patients.

Field of Use
The intent is to offer regenerative treatment options to patients, based on Licensor products and technologies like MyoCell and MyoCell SDF-1.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.